Circulatory Inflammatory Mediators in the Prediction of Anti-Tuberculous Drug-Induced Liver Injury Using RUCAM for Causality AssessmentArticle Published on 2021-07-252023-08-29 Journal: Biomedicines [Category] E형 간염, [키워드] Drug-induced liver injury hepatotoxicity Inflammatory mediators Prediction model RUCAM (Roussel Uclaf Causality Assessment Method) Tuberculosis [DOI] 10.3390/biomedicines9080891 PMC 바로가기 [Article Type] Article
A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trialSARS Cov-2 감염으로 입원한 환자에서 아스피린, 아토르바스타틴, 니코란딜을 사용한 삼중 요법의 효능과 안전성을 평가하기 위한 무작위 공개 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-07-152022-09-10 Journal: Trials [Category] SARS, 임상, [키워드] 1:1 ACHE Acute coronary syndrome Acute kidney injury acute renal failure adequate hydration adjuvant therapy Admission allergy ALT/AST Altered mental status Anti-inflammatory anticoagulation antipyretics Antithrombotic approved ARDS Aspirin AST/ALT atorvastatin bleeding Blinding block randomization Breastfeeding brown urine change characterized clinical clinical feature Clinical features Coagulopathy college Combination comorbid condition comorbid conditions comparator conducted control group coronary syndrome Corticosteroid Corticosteroids cough COVID-19 CPK creatine creatine kinase creatinine CRP current therapy Dexamethasone dissemination dose drug dysfunction Dyspnoea dysregulation effective Efficacy and safety element Endothelial dysfunction enrolled ethical committee evaluate excluded ferritin Fever followed by greater heparin hepatotoxicity Hospital admission hospital discharge Hospital mortality Hospital stay hospitalised patient Hospitalised patients hyperbilirubinemia hypoxia ICMR IEC immune dysregulation immunomodulatory impaired consciousness in-hospital mortality India Inflammation Inflammatory marker inflammatory markers Intervention intervention group intolerance intravenous Intravenous remdesivir invasive limit liver low molecular weight low molecular weight heparin management marker mechanical ventilation medication medications moderate muscle ache myalgia Myoglobin Myopathy myositis national guidelines Nicorandil Non-invasive number objective once daily Open-label open-label trial outcome oxygen Oxygen requirement oxygen support participant pathophysiologic pathophysiology Patient Platelet Platelet count Pneumonia positive Pregnancy Primary outcome progression protocol raised Rajendra Prasad Randomised control trial randomization randomize Randomized Randomized controlled trial randomly divided receive recruitment reducing mortality Registered registry Remdesivir renal failure reported respiratory rate rhabdomyolysis room air RT-PCR safety endpoint safety endpoints Sample size SARS-CoV-2 infected patient SARS-COV-2 infection Schematic screened Secondary outcomes Sepsis serum serum markers severe disease Shock significant interaction SpO2 Standard Standard of care starting dose statin statins Study design Study protocol substrates supplementary material Symptom Symptomatic treatment Tablet therapeutic therapeutic agent therapy thrombocytopenia Treatment Trial Trial registration two-arm parallel ULN Urine weakness website [DOI] 10.1186/s13063-021-05361-y PMC 바로가기 [Article Type] Letter
Zanubrutinib-induced liver injury: a case report and literature reviewCase Report Published on 2021-05-292023-08-28 Journal: BMC Gastroenterology [Category] E형 간염, [키워드] Case report Drug-induced liver injury hepatotoxicity RUCAM zanubrutinib [DOI] 10.1186/s12876-021-01825-2 PMC 바로가기 [Article Type] Case Report
The Use of In Silico Tools for the Toxicity Prediction of Potential Inhibitors of SARS-CoV-2SARS-CoV-2의 잠재적 억제제의 독성 예측을 위한 In Silico 도구의 사용Article Published on 2021-04-122022-09-10 Journal: Alternatives to Laboratory Animals [Category] MERS, 신약개발, 치료법, 치료제, [키워드] in silico toxicology adverse effects approval assist carcinogenicity Cardiotoxicity chymotrypsin Compound compounds computational toxicology Consensus Convalescent plasma therapy coronavirus coronavirus disease COVID-19 cysteine cysteine protease drug Drug development effort Endpoint exhibited hepatotoxicity in silico inhibitor inhibitors lead limitations Mutagenicity nucleocapsid protein positive Potential predict predicted prediction profiles protease Regulatory reported Repurposed drugs repurposing SARS-CoV-2 severe adverse effect silico studies therapeutic intervention Toxicity toxicity prediction were assessed were used [DOI] 10.1177/02611929211008196 PMC 바로가기 [Article Type] Article
Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors2019년 코로나바이러스 질환 환자의 약물 유발 간 손상: 렘데시비르와 P-당단백질 억제제의 잠재적 상호작용Case Reports Published on 2021-04-082022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 치료제, [키워드] COVID-19 drug-induced drug–drug interaction hepatotoxicity inhibitor inhibitors Interaction P-glycoprotein Patient physician Potential prescription receiving Remdesivir therapy with COVID-19 [DOI] 10.1093/cid/ciaa883 PMC 바로가기 [Article Type] Case Reports
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trialCOVID-19(FLARE) 외래 환자의 조기 항바이러스 치료: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-03-082022-09-01 Journal: Trials [Category] SARS, 임상, 진단, 치료기술, 치료제, [키워드] 24 hours 48 hour 48 hours absence admitted to ICU aetiology age ALT Analysis Anosmia anticipated antiviral therapy Antiviral treatment antivirals Appendix Arm arrhythmia AST Asthma Asymptomatic Autoimmune blinded to treatment Blinding blood sample BMI Breastfeeding childbearing potential Cholangitis chronic chronic hepatitis Chronic kidney disease chronic liver disease chronic respiratory disease cirrhosis clinical condition collected combination therapy Comorbidity concealed Concomitant concomitant medications conducted COPD coryza cough COVID-19 COVID-19 disease COVID-19 vaccine criteria current Date Day decrease defined Deleterious detectable diabetes died disease dissemination dose double-blind Duration early treatment effective EGFR element enrolled enrolment Ethnicity examined exclusion criteria factorial design Favipiravir female female participant Fever followed by Free Gender headache heart disease Hepatitis hepatotoxicity HIV infection hospital hospitalisation hypersensitivity hypertension in viral include inclusion criteria ingredient investigator investigators Ischaemic heart disease Kidney disease liver Liver disease London Lopinavir Lopinavir/ritonavir malaise male participant male participants measure medication Mutation myalgia Myocardial infarction no symptom non-hospitalised not limited number obesity objective observational studies observational study oral outcome Outpatient outpatients participant Participants partner percentage pharmacokinetic phase IIa Placebo placebo-controlled placebo-controlled trial positive presence or absence Primary outcome Proportion of participant Protease inhibitor protocol randomised randomised controlled trial Rate Registered Registration respiratory Respiratory disease risk Ritonavir Safety Saliva saliva samples Sample size SARS-CoV-2 secondary Secondary outcomes Shortness of breath smoker smoking smoking status Stage status steatohepatitis Stool Study protocol supplementary material Symptom symptom onset symptomatic tested therapy Toxicity Treatment treatment allocation Trial trial medication Trial registration undetectable United Kingdom upper respiratory tract vaccine trial valvular valvular heart disease Viral Viral load website with COVID-19 [DOI] 10.1186/s13063-021-05139-2 PMC 바로가기 [Article Type] Letter
A Critical Perspective on 3D Liver Models for Drug Metabolism and Toxicology StudiesReview Published on 2021-02-222023-08-30 Journal: Frontiers in Cell and Developmental Biology [Category] E형 간염, [키워드] in vitro liver model Diclofenac fit-for-purpose models hepatotoxicity Paracetamol three-dimensional culture Troglitazone [DOI] 10.3389/fcell.2021.626805 PMC 바로가기 [Article Type] Review
Drug-drug interactions with candidate medications used for COVID-19 treatment: An overviewCOVID-19 치료에 사용되는 후보 약물과의 약물-약물 상호작용: 개요Review Published on 2021-02-012022-09-11 Journal: Pharmacology Research & Perspectives [Category] 진단, 치료제, [키워드] Adverse reactions Chloroquine concomitant use coronavirus disease Coronavirus disease 2019 COVID-19 drug-drug interaction drugs hepatotoxicity increased risk Infection Interaction Kaletra Lopinavir Lopinavir/ritonavir medication medications occur occurred Patient Remdesivir retinopathy ribavirin risk Ritonavir serious adverse reaction Serious adverse reactions Tocilizumab Treatment [DOI] 10.1002/prp2.705 PMC 바로가기 [Article Type] Review
COVID 19 and liver: An A-Z literature reviewCOVID 19와 간: A-Z 문헌 검토Review Published on 2021-02-012022-09-11 Journal: Digestive and liver disease : official journal of [Category] SARS, 치료제, [키워드] advanced liver disease changed Clinical course coronavirus COVID -19 COVID 19 COVID-19 COVID-19 infected patient COVID-19 infection Critical derangement disease disease course drug Drug hepatotoxicity Effect hepatic injury Hepatocellular carcinoma hepatotoxicity Immunocompromised patient Immunocompromised patients Inflammatory response Intensive Laboratory literature review liver Liver damage Liver disease Liver function Liver injury liver pathology Liver pathology. liver transplant management marker occur outcome pandemic parameter pathological findings pathology pathophysiology patients Perspective prognostic effect proportion provide recommendations severe or critical illness Surveillance Temporal Therapeutic approach therapy Variation Viral viral infection [DOI] 10.1016/j.dld.2020.09.010 PMC 바로가기 [Article Type] Review
An In-vivo Study into the Effects of Schisandrin B in the Liver, Spleen, Kidney, and Brain of Acute Thioacetamide-intoxicated MiceOriginal Article Published on 2021-01-012024-09-02 Journal: Iranian Journal of Pharmaceutical Research : IJPR [Category] 대상포진, [키워드] Apoptosis hepatotoxicity Inflammasome schisandrin B Thioacetamide [DOI] 10.22037/ijpr.2021.115154.15225 PMC 바로가기 [Article Type] Original Article